(Q46922097)

26 December 2017

title

Rituximab for refractory focal segmental glomerulosclerosis (English)

1 reference

26 December 2017

focal segmental glomerulosclerosis

main subject

1 reference

1 reference

Makiko Nakayama

1

1 reference

26 December 2017

Koichi Kamei

2

1 reference

26 December 2017

Kandai Nozu

3

1 reference

26 December 2017

Kentaro Matsuoka

4

1 reference

26 December 2017

Atsuko Nakagawa

5

1 reference

26 December 2017

Mayumi Sako

6

1 reference

26 December 2017

Kazumoto Iijima

7

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

published in

Pediatric Nephrology

1 reference

26 December 2017

volume

23

1 reference

26 December 2017

page(s)

481-485

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s00467-007-0640-x

exact match

0 references

cites work

Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00467-007-0640-X

Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

21 January 2018

1 reference

12 December 2020

The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects.

1 reference

12 December 2020

Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

1 reference

12 December 2020

Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

1 reference

12 December 2020

Recent progress in the understanding of B-cell functions in autoimmunity

1 reference

12 December 2020

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

1 reference

12 December 2020

"The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma

1 reference

12 December 2020

Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab

1 reference

12 December 2020

Rituximab therapy for steroid-dependent minimal change nephrotic syndrome

1 reference

12 December 2020

Rituximab for idiopathic membranous nephropathy

1 reference

12 December 2020

Therapeutic approach to FSGS in children

1 reference

12 December 2020

Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome

1 reference

12 December 2020

Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment

1 reference

12 December 2020

Rituximab in patients with the steroid-resistant nephrotic syndrome

1 reference

12 December 2020

Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis

1 reference

12 December 2020

Drug insight: rituximab in renal disease and transplantation

1 reference

12 December 2020

Tolerability and safety of rituximab (MabThera).

1 reference

12 December 2020

Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations

1 reference

12 December 2020

Recurrent and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry

1 reference

12 December 2020

10.1007/S00467-007-0640-X

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17973121

1 reference

26 December 2017